Relationship Between Liver Cancer and Sarcopenia

June 14, 2022 updated by: Gang Chen, MD, First Affiliated Hospital of Wenzhou Medical University

The Effect of Sarcopenia on Hepatocellular Carcinoma After Hepatectomy

By tracking the short-term and long-term results of patients after hepatectomy, the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after hepatectomy was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

All implementation details are based on the newest EWGSOP definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes of patients after hepatectomy, the differences were analyzed and the relationship between sarcopenia and liver cancer was explored.

Study Type

Observational

Enrollment (Anticipated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Zhejiang
      • Wenzhou, Zhejiang, China, 325000
        • Gang Chen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with preoperative clinical diagnosis of liver cancer admitted to the hepatobiliary surgery department and received standard tests and questionnaires.

Description

Inclusion Criteria:

  • Patients with preoperative clinical diagnosis of liver cancer
  • No cancer other than liver cancer has been diagnosed
  • Age ≥18 years

Exclusion Criteria:

  • Patients who could not complete the standard tests and questionnaires
  • Patients who did not accept liver resection after evaluation of treatment plan
  • Patients who had other concomitant preoperative causes of muscle weakness (injury, fracture, stroke, etc.)
  • Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short-term postoperative results
Time Frame: 3 months
Postoperative complications；90 days readmission rate
3 months
Long-term results after operation
Time Frame: 10 years
Overall survival; Disease free survival
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative hospitalization time
Time Frame: 2 months
Time window from the day of operation to the day of discharge.
2 months
Hospitalization expenses
Time Frame: 2 months
All hospitalization expenses, including drug expenses, operation expenses, anesthesia expenses, nursing expenses and other expenses.
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Collaborators

Qilu Hospital of Shandong University
The Second Hospital of Shandong University

Investigators

  • Principal Investigator: Gang Chen, M.D., First Affiliated Hospital of Wenzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2020

Primary Completion (Actual)

August 11, 2021

Study Completion (Anticipated)

August 28, 2025

Study Registration Dates

First Submitted

April 9, 2022

First Submitted That Met QC Criteria

April 15, 2022

First Posted (Actual)

April 21, 2022

Study Record Updates

Last Update Posted (Actual)

June 15, 2022

Last Update Submitted That Met QC Criteria

June 14, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • sarcopenia

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on gait speed; ct scan;grip strength and chair stand test

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe